BioAtla, Inc.
NASDAQ: BCAB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jay Short
- Employees
- 61
- Headquarters
- San Diego, United States
- IPO year
- 2020
- Market cap
- $4.8M
- Website
- https://www.bioatla.com
Loading BCAB…
Loading profile data…Frequently asked questions about BCAB
What does BioAtla, Inc. (BCAB) do?
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated...
Where does BCAB trade?
BioAtla, Inc. (BCAB) trades on the NASDAQ Global Market.
What sector is BCAB in?
BioAtla, Inc. (BCAB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioAtla, Inc.?
Jay Short is the chief executive officer of BioAtla, Inc. (BCAB).
Where is BioAtla, Inc. headquartered?
BioAtla, Inc. is headquartered in United States.
Does BCAB pay a dividend?
BioAtla, Inc. (BCAB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BCAB go public?
BioAtla, Inc. (BCAB) completed its initial public offering in 2020.